# IMMUNIC, INC. (IMUX) — management_change/board [announced]
Source: SEC API (secapi.ai) · situation sit_f37d22a60eb6f91f081d · retrieved 2026-08-17T11:56:21.770Z

## Overview
Immunic, Inc. is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, with its lead program vidofludimus calcium (IMU-838) currently in Phase 3 clinical trials for relapsing multiple sclerosis.

On August 7, 2026, Immunic, Inc. terminated the employment of Chief Executive Officer Dr. Daniel Vitt effective immediately. Under the Separation Agreement, Dr. Vitt received severance consisting of: (i) a salary payment of $670,000 (first 12 months) paid in a lump sum, with the remaining 4.5 months paid in five monthly installments beginning one year after the Release Effective Date; (ii) an aggregate bonus payment of $276,375 (75% of his 2026 target bonus); (iii) healthcare reimbursement up to €1,500 per month for 18 months; and (iv) 100% acceleration of all outstanding equity awards with a three-year exercise window. Dr. Vitt transitioned to Chair of the Scientific Advisory Board and agreed to serve as a consultant to the Company's subsidiary for 12 months at a monthly retainer of €15,000, working up to 15 hours per month. He is subject to non-competition and non-solicitation covenants through the consulting period and for six months thereafter.

## Terms
- Consideration: cash

## Key dates
- Announced 2026-08-11

## Timeline
- 2026-08-11 · 8-K (0001193805-26-001071): 8-K - IMMUNIC, INC. — *Immunic, Inc. is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, with its lead program vidofludimus calcium (IMU-838) currently in Phase 3 clinical trials for relapsing multiple sclerosis.* On August 7, 2026, Immunic, Inc. terminated the employment of Chief Executive Officer Dr. Daniel Vitt effective immediately. Under the Separation Agreement, Dr. Vitt received severance consisting of: (i) a salary payment of $670,000 (first 12 months) paid in a lump sum, with the remaining 4.5 months paid in five monthly installments beginning one year after the Release Effective Date; (ii) an aggregate bonus payment of $276,375 (75% of his 2026 target bonus); (iii) healthcare reimbursement up to €1,500 per month for 18 months; and (iv) 100% acceleration of all outstanding equity awards with a three-year exercise window. Dr. Vitt transitioned to Chair of the Scientific Advisory Board and agreed to serve as a consultant to the Company's subsidiary for 12 months at a monthly retainer of €15,000, working up to 15 hours per month. He is subject to non-competition and non-solicitation covenants through the consulting period and for six months thereafter.
  https://www.sec.gov/Archives/edgar/data/1280776/0001193805-26-001071.txt

## Citations
- 0001193805-26-001071 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119380526001071